ORIENTBIO, Inc. (002630) Stock Statistics & Valuation Metrics

ORIENTBIO, Inc. has a market cap or net worth of ₩54.00B. The enterprise value is ―.

ORIENTBIO, Inc. has 59,291,504 shares outstanding. The number of shares has decreased by -2.65% in one year.

ORIENTBIO, Inc.’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -5.74%.

The current PE Ratio of ORIENTBIO, Inc. is ―. ORIENTBIO, Inc.’s PEG ratio is 0.23.

In the last 12 months, ORIENTBIO, Inc. had revenue of 29.75B and earned -4.57B in profits. Earnings per share was -77.03.

In the last 12 months, operating cash flow was 2.60B and capital expenditures -2.05B, giving a free cash flow of 546.36M billion.

ORIENTBIO, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

ORIENTBIO, Inc. upcoming earnings date is Aug 19, 2026, TBA (Not Confirmed).

ORIENTBIO, Inc. as a current ratio of 7.82, with Debt / Equity ratio of 2.82%

In the past 12 months, ORIENTBIO, Inc. has paid 0.00 in taxes.

ORIENTBIO, Inc. EV to EBITDA ratio is -28.90, with an EV/FCF ratio of 118.00.

ORIENTBIO, Inc. has ₩32.77B in cash and marketable securities with ₩1.94B in debt, giving a net cash position of ₩30.84B billion.

Gross margin is 16.38%, with operating margin of -14.93%, and net profit margin of -15.35%.

The average price target for ORIENTBIO, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―